Genomics & Informatics

Korea Genome Organization (한국유전체학회)
권호 표지
DOI QR코드

DOI QR Code

Identification of key genes and functional enrichment analysis of liver fibrosis in nonalcoholic fatty liver disease through weighted gene co-expression network analysis

  • Yue Hu (Shenzhen InnoStar Institute of Biomedical Safety Evaluation and Research Co., Ltd.) ;
  • Jun Zhou (Shenzhen InnoStar Institute of Biomedical Safety Evaluation and Research Co., Ltd.)
  • Received : 2023.07.31
  • Accepted : 2023.10.24
  • Published : 2023.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a common type of chronic liver disease, with severity levels ranging from nonalcoholic fatty liver to nonalcoholic steatohepatitis (NASH). The extent of liver fibrosis indicates the severity of NASH and the risk of liver cancer. However, the mechanism underlying NASH development, which is important for early screening and intervention, remains unclear. Weighted gene co-expression network analysis (WGCNA) is a useful method for identifying hub genes and screening specific targets for diseases. In this study, we utilized an mRNA dataset of the liver tissues of patients with NASH and conducted WGCNA for various stages of liver fibrosis. Subsequently, we employed two additional mRNA datasets for validation purposes. Gene set enrichment analysis (GSEA) was conducted to analyze gene function enrichment. Through WGCNA and subsequent analyses, complemented by validation using two additional datasets, we identified five genes (BICC1, C7, EFEMP1, LUM, and STMN2) as hub genes. GSEA analysis indicated that gene sets associated with liver metabolism and cholesterol homeostasis were uniformly downregulated. BICC1, C7, EFEMP1, LUM, and STMN2 were identified as hub genes of NASH, and were all related to liver metabolism, NAFLD, NASH, and related diseases. These hub genes might serve as potential targets for the early screening and treatment of NASH.

Keywords

References

  1. Ahmed A, Wong RJ, Harrison SA. Nonalcoholic fatty liver disease review: diagnosis, treatment, and outcomes. Clin Gastroenterol Hepatol 2015;13:2062-2070. https://doi.org/10.1016/j.cgh.2015.07.029
  2. Machado MV, Diehl AM. Pathogenesis of nonalcoholic steatohepatitis. Gastroenterology 2016;150:1769-1777. https://doi.org/10.1053/j.gastro.2016.02.066
  3. Nasr P, Ignatova S, Kechagias S, Ekstedt M. Natural history of nonalcoholic fatty liver disease: a prospective follow-up study with serial biopsies. Hepatol Commun 2018;2:199-210. https://doi.org/10.1002/hep4.1134
  4. Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 2018;15:11-20. https://doi.org/10.1038/nrgastro.2017.109
  5. Marengo A, Rosso C, Bugianesi E. Liver cancer: connections with obesity, fatty liver, and cirrhosis. Annu Rev Med 2016;67: 103-117. https://doi.org/10.1146/annurev-med-090514-013832
  6. Pavlov CS, Casazza G, Nikolova D, Tsochatzis E, Burroughs AK, Ivashkin VT, et al. Transient elastography for diagnosis of stages of hepatic fibrosis and cirrhosis in people with alcoholic liver disease. Cochrane Database Syst Rev 2015;1:CD010542.
  7. Fraile JM, Palliyil S, Barelle C, Porter AJ, Kovaleva M. Non-alcoholic steatohepatitis (NASH): a review of a crowded clinical landscape, driven by a complex disease. Drug Des Devel Ther 2021;15:3997-4009. https://doi.org/10.2147/DDDT.S315724
  8. Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med 2018;24:908-922. https://doi.org/10.1038/s41591-018-0104-9
  9. Schuster S, Cabrera D, Arrese M, Feldstein AE. Triggering and resolution of inflammation in NASH. Nat Rev Gastroenterol Hepatol 2018;15:349-364. https://doi.org/10.1038/s41575-018-0009-6
  10. Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics 2008;9:559.
  11. Tian Z, He W, Tang J, Liao X, Yang Q, Wu Y, et al. Identification of important modules and biomarkers in breast cancer based on WGCNA. Onco Targets Ther 2020;13:6805-6817. https://doi.org/10.2147/OTT.S258439
  12. Niemira M, Collin F, Szalkowska A, Bielska A, Chwialkowska K, Reszec J, et al. Molecular signature of subtypes of non-small-cell lung cancer by large-scale transcriptional profiling: identification of key modules and genes by weighted gene co-expression network analysis (WGCNA). Cancers (Basel) 2019;12:37.
  13. Clough E, Barrett T. The Gene Expression Omnibus Database. Methods Mol Biol 2016;1418:93-110. https://doi.org/10.1007/978-1-4939-3578-9_5
  14. Sahlabadi A, Chandren Muniyandi R, Sahlabadi M, Golshanbafghy H. Framework for parallel preprocessing of microarray data using Hadoop. Adv Bioinformatics 2018;2018:9391635.
  15. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 2015;43:e47.
  16. Liao Y, Wang J, Jaehnig EJ, Shi Z, Zhang B. WebGestalt 2019: gene set analysis toolkit with revamped UIs and APIs. Nucleic Acids Res 2019;47:W199-W205. https://doi.org/10.1093/nar/gkz401
  17. Wickham H. ggplot2: Elegant Graphics for Data Analysis. New York: Springer-Verlag, 2016.
  18. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005;102:15545-15550. https://doi.org/10.1073/pnas.0506580102
  19. Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 2012;16:284-287. https://doi.org/10.1089/omi.2011.0118
  20. Liberzon A, Birger C, Thorvaldsdottir H, Ghandi M, Mesirov JP, Tamayo P. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst 2015;1:417-425. https://doi.org/10.1016/j.cels.2015.12.004
  21. Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet 2021;397:2212-2224. https://doi.org/10.1016/S0140-6736(20)32511-3
  22. Kucukoglu O, Sowa JP, Mazzolini GD, Syn WK, Canbay A. Hepatokines and adipokines in NASH-related hepatocellular carcinoma. J Hepatol 2021;74:442-457. https://doi.org/10.1016/j.jhep.2020.10.030
  23. Krishnan A, Li X, Kao WY, Viker K, Butters K, Masuoka H, et al. Lumican, an extracellular matrix proteoglycan, is a novel requisite for hepatic fibrosis. Lab Invest 2012;92:1712-1725. https://doi.org/10.1038/labinvest.2012.121
  24. Chang Y, He J, Xiang X, Li H. LUM is the hub gene of advanced fibrosis in nonalcoholic fatty liver disease patients. Clin Res Hepatol Gastroenterol 2021;45:101435.
  25. Hou W, Janech MG, Sobolesky PM, Bland AM, Samsuddin S, Alazawi W, et al. Proteomic screening of plasma identifies potential noninvasive biomarkers associated with significant/advanced fibrosis in patients with nonalcoholic fatty liver disease. Biosci Rep 2020;40:BSR20190395.
  26. Yang Z, Han X, Wang K, Fang J, Wang Z, Liu G. Combined with multiplex and network analysis to reveal the key genes and mechanisms of nonalcoholic fatty liver disease. Int Immunopharmacol 2023;123:110708.
  27. He W, Huang C, Zhang X, Wang D, Chen Y, Zhao Y, et al. Identification of transcriptomic signatures and crucial pathways involved in non-alcoholic steatohepatitis. Endocrine 2021;73:52-64. https://doi.org/10.1007/s12020-021-02716-y
  28. Bieche I, Asselah T, Laurendeau I, Vidaud D, Degot C, Paradis V, et al. Molecular profiling of early stage liver fibrosis in patients with chronic hepatitis C virus infection. Virology 2005;332:130-144. https://doi.org/10.1016/j.virol.2004.11.009
  29. Arendt BM, Teterina A, Pettinelli P, Comelli EM, Ma DW, Fung SK, et al. Cancer-related gene expression is associated with disease severity and modifiable lifestyle factors in non-alcoholic fatty liver disease. Nutrition 2019;62:100-107. https://doi.org/10.1016/j.nut.2018.12.001
  30. Zhao R, Peng C, Song C, Zhao Q, Rong J, Wang H, et al. BICC1 as a novel prognostic biomarker in gastric cancer correlating with immune infiltrates. Int Immunopharmacol 2020;87:106828.
  31. Zhu Y, Zhang H, Jiang P, Xie C, Luo Y, Chen J. Transcriptional and epigenetic alterations in the progression of non-alcoholic fatty liver disease and biomarkers helping to diagnose non-alcoholic steatohepatitis. Biomedicines 2023;11:970. https://doi.org/10.3390/biomedicines11030970
  32. Chiang JYL, Ferrell JM. Bile acid metabolism in liver pathobiology. Gene Expr 2018;18:71-87. https://doi.org/10.3727/105221618X15156018385515